Stock·NYSE·Basic Materials
Cemex S.A.B. de C.V. (CX)
- Market cap
- $14.70B
- Dividend yield
- None
- Street target
- $15.00median of 15 analysts
- 52-week range
- $9.30 $13.67
CX stock forecast today
Where CX stands today, and what CleaRank Financial AI makes of it.
CX at a glance
Cemex S.A.B. de C.V. (CX): Hold, 48/100 on CleaRank's AI score.
- Trend Down: the price is below both its 50- and 200-day moving averages ($10.25 and $11.68).
- Earnings CX beat estimates in 5 of its last 8 quarters, yet fell the next day after 4 of those beats.
- Insiders Insiders sold $426K and made no open-market purchases over the last 18 months.
Figures as of October 26, 2026.
CleaRank Financial AI
CleaRank rates Cemex S.A.B. de C.V. (CX) Hold, with a model score of 48/100.
The analysts' outlook lifts the score most: 12 of 15 analysts rate it a buy and the median target is 47.2% above the price. The trend holds it back most: the price is 12.76% below its 200-day average and 0.58% below its 50-day average, and the 50-day average is 12.26% below the 200-day. The 50-day average stands at $10.25 and the 200-day at $11.68. Over the past year the price rose 8.87%.
Only on CleaRank
Figures we compute ourselves from CX's own price, earnings and insider-filing history. Tap one to see it in context.
CX stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
0/4Price above its 50-day average ›
The price of $10.19 is 0.6% below the 50-day simple moving average of $10.25.Price above its 200-day average ›
The price is 12.8% below the 200-day simple moving average of $11.68.50-day average above the 200-day ›
The 50-day average ($10.25) is 12.3% below the 200-day average ($11.68), the arrangement of a falling longer-term trend.In the upper half of its 52-week range ›
The price sits at 20% of its 52-week range, between $9.30 and $13.67.
CX share price
Pick a period: each tab shows how far CX has moved over it, to the last close.
Today's trading
Where CX sits inside today's range and its 52-week range.
CX fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
3/3P/S below the sector median ›
The price-to-sales ratio of 0.86 is 79.4% below the sector median of 4.2.Profitable over the last 12 months ›
Net income over the last 12 months was $513.4M on revenue of $17.0B, a net margin of 3.0%.Beat estimates in most recent reports ›
CX beat the EPS estimate in 5 of its last 8 reports.
Key statistics
The headline figures for CX.
As of October 26, 2026, CX trades at $10.19, with a market value of $14.70B.
What the numbers say
CleaRank Financial AI's reading of CX's valuation, growth and risks.
On sales the picture differs: the P/S of 0.86 is 79.5% below the sector median P/S of 4.2.
Profitability shows a net margin of 2.83% and an operating margin of 13.74%, with a return on equity of 4.01%, below the sector median of 17.9%. It also reports debt-to-equity of 0.54.
CX reported $0.24 per share for its most recent quarter, reported on July 23, 2026. That was ahead of the $0.18 analyst estimate, a beat of 33.33%. The share price nonetheless slid 1.63% in the first session after the report.
The earnings record shows 5 beats in 8 reports, but beats have not guaranteed gains: the stock fell the next day after 4 of them. Looking ahead, analysts expect EPS of $0.82 this fiscal year (growth of 57.0%) and $0.91 the year after (growth of 10.8%).
CX typically moves about 2.13% in a day, and its beta against the S&P 500 is 0.81. For as long as the price stays under both moving averages, the downtrend remains a risk in its own right. The price is also 25.46% below the 52-week high of $13.67.
CX against the Basic Materials sector
How CX compares with the median Basic Materials stock CleaRank tracks.
Price to sales vs sector: On price-to-sales, the yardstick used here in place of P/E, CX trades at 0.8639x, far below the sector average of 4.20x.
Return vs XLB: Since May 14, 2025, CX has gained 49.4% against a gain of 20.5% for XLB.
Performance against XLB
CX and the Basic Materials sector fund over the same days.
Revenue and earnings
How much CX sells, and how much of it becomes profit.
Revenue growth: Revenue fell 0.4% in FY2025 to $16.1B, from $16.2B a year earlier.
Profit margin: The net margin was 6.0% in FY2025, up from 5.9% the year before.
Profitable: CX earned $970M in FY2025.
Earnings reality check
Did CX beat what analysts expected, and how did the stock react?
Earnings record: CX beat the analyst estimate in 5 of the last 8 quarters.
Market reaction: The stock fell in the first session after 4 of those 5 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Jul 23, 2026after close | $0.18 | $0.24 | +33.33% | -1.63% | -2.69% |
| Apr 23, 2026after close | $0.11 | $0.17 | +54.55% | -1.20% | -1.68% |
| Feb 5, 2026after close | $0.20 | -$0.24 | -220.00% | +2.09% | +2.68% |
| Oct 28, 2025after close | $0.17 | $0.18 | +5.88% | -0.19% | -2.43% |
| Jul 24, 2025after close | $0.19 | $0.22 | +15.79% | +1.94% | +5.45% |
| Apr 28, 2025after close | $0.05 | $0.50 | +900.00% | -1.62% | -1.29% |
| Feb 6, 2025after close | $0.04 | $0.03 | -25.00% | -1.33% | -1.77% |
| Oct 28, 2024after close | $0.19 | $0.14 | -26.32% | -3.85% | -5.31% |
As of October 26, 2026, CX has beaten the analyst EPS estimate in 5 of its last 8 reported quarters and fell in the first trading session after 4 of those beats; its latest report, on July 23, 2026, came in 33.33% above the estimate and the stock moved -1.63% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
CX AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 53.3, in neutral territory.RSI above 50 ›
An RSI of 53.3 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank Financial AI analysis of CX
The score, the reasoning behind it, and what could move the price next.
Cemex S.A.B. de C.V. (CX) sits beneath both of its major moving averages. The price is 0.58% below its 50-day average of $10.25 and 12.76% below the 200-day average of $11.68. Sitting at 20% of its 52-week range, the stock is 9.57% above the 52-week low of $9.30, with the current price at $10.19.
The short and long run point different ways: the price rose 4.94% over the past month, fell 16.48% over the past three months and rose 8.87% over the past year. The price fell 0.10% in the last session on volume 75.0% above its average. On momentum, the 14-day RSI reads 53.3, in the neutral zone, with the MACD line positive.
Analyst upgrade ›
Citigroup upgraded it to Buy from Neutral on October 15, 2026.
Source: Analyst action, Citigroup, October 15, 2026
Earnings beat, but the stock fell ›
The July 23, 2026 report beat the EPS estimate by 33.33%, and the share price fell 1.63% in the first session after it.
Source: Earnings report, July 23, 2026
- Keep an eye on the two nearest levels: the 50-day SMA at $10.25 sits above the price, and the 20-day EMA at $10.03 sits below it.
- The 14-day RSI reads 53.3, in the neutral zone, with the MACD line positive; readings above 70 or below 30 mark stretched momentum.
- Following the July 23, 2026 report, the share price dropped 1.63% in the first session. Across the last 8 reports, CX beat estimates in 5.
The downtrend stays in place while CX is below both its 50-day average at $10.25 and its 200-day average at $11.68; a close back above the 50-day would be the first step of a repair. The 50-day SMA at $10.25 is the first hurdle overhead.
If the price falls, the 20-day EMA at $10.03 is the first level it would reach below the current price.
Technical indicators
Momentum and trend for CX, from its daily closes.
As of October 26, 2026, with CX at $10.19, its 14-day RSI is 53.3 (neutral territory), its 50-day simple moving average is $10.25 and its 200-day is $11.68.
Calculated by CleaRank on daily closes as of October 26, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What CX moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 26, 2026, CX's 1-year correlation of daily returns is +0.47 with S&P 500 (SPY), +0.44 with Nasdaq 100 (QQQ), +0.31 with Bitcoin (BTC) and +0.31 with gold (XAU).
CX price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
3/3Most analysts rate it a buy ›
12 of 15 analysts rate it a buy or strong buy, 3 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $15.00 is 47.2% above the price.More buy ratings than three months ago ›
12 of 15 rate it a buy now, against 11 of 15 three months ago.
CX Wall Street View
12-month price targets
The price, $10.19, sits below every analyst's target.
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 15, 2026 | Citigroup | Upgrade | Buy |
| Oct 9, 2026 | RBC Capital | Maintains | Sector Perform |
| Jul 24, 2026 | RBC Capital | Maintains | Sector Perform |
| Jul 24, 2026 | Barclays | Maintains | Overweight |
| Jul 14, 2026 | Scotiabank | Maintains | Sector Outperform |
| Jul 8, 2026 | JP Morgan | Maintains | Overweight |
As of October 26, 2026, 15 Wall Street analysts cover CX: 12 rate it a buy or strong buy, 3 a hold and 0 a sell or strong sell. Their 12-month price targets range from $11.00 to $20.00. The median CX price target is $15.00, 47.2% above the price of $10.19.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
CX trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
CX trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Entry Strategies pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from CX's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much CX tends to move, against the market and on its own.
CX price history and drawdowns
CX's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
1/4Average daily move under 2% ›
The price has moved 2.13% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 82.3%, from July 2017 to March 2020, regained by October 2025.Most 1-year holds ended higher ›
47% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $12,427, against $42,015 in the S&P 500 (SPY).
CX Drawdowns & Recovery
As of October 26, 2026, CX's worst peak-to-trough fall over the last 10 years with dividends reinvested was -82.3% (July 2017 to March 2020); it regained that peak by October 2025, 67 months after the low, and 47% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into CX in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: CX trailed the S&P 500 over this period: $12,427 against $42,015.
A $10,000 investment in CX in October 2016 would be worth about $12,427 today with dividends reinvested, compared with about $42,015 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to CX, and which have not.
Strongest month, January: an average of +9.06%, up in 9 of 10 years.
Weakest month, February: an average of -6.80%, up in 2 of 10 years.
This month, October: has averaged -5.15%, up in 4 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, CX's strongest calendar month has been January (average +9.06%, up in 9 of 10 years) and its weakest February (average -6.80%, up in 2 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
CX stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in CX, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in CX today could grow to about $11,723 by 2030 in the base case, with a 90th-percentile outcome near $35,254 and a 10th-percentile outcome around $3,898. Projections are statistical simulations, not guarantees.
CX Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $11.95 for CX by 2030 in the base case, from $10.19 today (1.2x over 4 years). The 10th-percentile path ends near $3.97. These are outcomes of a Monte Carlo simulation run on CX's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $6.11 | $10.60 | $18.39 | |
| 2028 | $5.06 | $11.03 | $24.03 | |
| 2029 | $4.42 | $11.48 | $29.79 | |
| 2030 | $3.97 | $11.95 | $35.92 |
Method: a lognormal simulation of CX's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
CX insider trading
What the people running the company have bought and sold.
CX insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: No insider bought CX shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 26, 2026, CX insiders reported 1 open-market sale worth $426K and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jul 1, 2026 | Merla Jaime Martinez
Officer
|
Grant | 7.7K | - |
| Jun 15, 2026 | Hernandez Luis Echavez
Officer
|
Grant | 81.7K | - |
| Jun 15, 2026 | Cantu Alejandro Alberto Ramirez
Officer
|
Grant | 30.5K | - |
| Jun 12, 2026 | Flores Jose Antonio Gonzalez
Officer
|
Grant | 75.5K | - |
| May 1, 2026 | Cobian Mauricio Doehner
Officer
|
Grant | 38.3K | - |
| May 1, 2026 | Dominguez Jaime Muguiro
Chief Executive Officer
|
Grant | 333.6K | - |
| May 1, 2026 | Madero Roger Saldana
Officer
|
Grant | 37.1K | - |
| May 1, 2026 | Lozano Rogelio Zambrano
Director
|
Grant | 205.6K | - |
| Apr 28, 2026 | Herrera Jesus Vicente Gonzalez
Officer
|
Sell | 35.0K | $425.6K |
Source: TwelveData, from reported insider filings
CX stock forecast: questions people ask
Answered from the figures on this page, as of October 26, 2026.